How have VIRI shares performed in 2024?

Virios Therapeutics' stock was trading at $0.5750 at the start of the year. Since then, VIRI shares have decreased by 24.3% and is now trading at $0.4355. View the best growth stocks for 2024 here .

Are investors shorting Virios Therapeutics?

Virios Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 217,500 shares, an increase of 27.8% from the March 15th total of 170,200 shares. Based on an average daily trading volume, of 386,400 shares, the days-to-cover ratio is currently 0.6 days. View Virios Therapeutics' Short Interest .

When is Virios Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VIRI earnings forecast .

How were Virios Therapeutics' earnings last quarter?

Virios Therapeutics, Inc. (NASDAQ:VIRI) announced its earnings results on Thursday, February, 29th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.03.

When did Virios Therapeutics IPO?

Virios Therapeutics (VIRI) raised $30 million in an initial public offering (IPO) on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

How do I buy shares of Virios Therapeutics?

Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VIRI

Virios Therapeutics (VIRI) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free VIRI Stock Alerts

$0.44

-0.01 (-3.20%)

(As of 04:00 PM ET)

Compare

Today's Range: $0.44
▼
$0.46
50-Day Range: $0.31
▼
$0.58
52-Week Range: $0.28
▼
$2.42

Volume: 59,246 shs
Average Volume: 359,481 shs
Market Capitalization: $8.39 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Virios Therapeutics alerts:

Virios Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.13% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.42
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.27) to ($0.30) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.20 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Virios Therapeutics.

3.0

Short Interest

Percentage of Shares Shorted
1.13% of the outstanding shares of Virios Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Virios Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Virios Therapeutics has recently increased by 27.79%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Virios Therapeutics does not currently pay a dividend.
Dividend Growth
Virios Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VIRI.

3.0

News and Social Media Coverage

News Sentiment
Virios Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Virios Therapeutics this week, compared to 1 article on an average week.
Search Interest
2 people have searched for VIRI on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Virios Therapeutics to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Virios Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.70% of the stock of Virios Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 9.05% of the stock of Virios Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Virios Therapeutics are expected to decrease in the coming year, from ($0.27) to ($0.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Virios Therapeutics is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Virios Therapeutics is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Virios Therapeutics has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Virios Therapeutics Stock (NASDAQ:VIRI)

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

VIRI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VIRI Stock News Headlines

April 14, 2024 | finance.yahoo.com

Virios Therapeutics, Inc. (VIRI)

April 13, 2024 | americanbankingnews.com

Virios Therapeutics, Inc. (NASDAQ:VIRI) Sees Large Growth in Short Interest

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 28, 2024 | investing.com

Virios Therapeutics seeks global patent for antiviral combo

March 26, 2024 | globenewswire.com

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

February 29, 2024 | investing.com

Virios Therapeutics announces salary cuts for employees and board

February 29, 2024 | markets.businessinsider.com

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

February 29, 2024 | globenewswire.com

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 28, 2024 | markets.businessinsider.com

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

February 28, 2024 | globenewswire.com

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

February 27, 2024 | investing.com

Virios Therapeutics Llc (VIRI)

February 25, 2024 | msn.com

Virios Therapeutics (VIRI) Price Target Increased by 14.29% to 4.08

February 9, 2024 | morningstar.com

Virios Therapeutics Inc Ordinary Shares VIRI

February 7, 2024 | finance.yahoo.com

VIRI: Moving IMC-2 into Phase 2 Program in Long COVID

February 6, 2024 | finance.yahoo.com

Fibromyalgia Treatment Market revenue to cross USD 536 Million by 2033, says Research Nester

January 23, 2024 | benzinga.com

Virios Therapeutics Stock (NASDAQ:VIRI) Dividends: History, Yield and Dates

January 22, 2024 | finanznachrichten.de

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

January 22, 2024 | finance.yahoo.com

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

January 2, 2024 | markets.businessinsider.com

Virios Therapeutics Reports Receipt Of FDA's Feedback On Requirements For Advancing IMC-2

January 2, 2024 | finance.yahoo.com

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

December 7, 2023 | morningstar.com

Virios Therapeutics Inc Ordinary Shares

November 14, 2023 | finance.yahoo.com

Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript

November 13, 2023 | finance.yahoo.com

VIRI: Provides Overview of Phase 3 Program in Fibromyalgia

November 13, 2023 | msn.com

Virios Therapeutics GAAP EPS of -$0.06 beats by $0.04

November 13, 2023 | finance.yahoo.com

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 13, 2023 | finance.yahoo.com

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

See More Headlines

Receive VIRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VIRI
CUSIP: N/A
CIK: 1818844
Web: www.virios.com
Phone: 866-620-8655
Fax: N/A
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-5,300,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -110.15%
Return on Assets: -100.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.60
Quick Ratio: 11.60

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.20 per share
Price / Book: 2.22

Miscellaneous

Outstanding Shares: 19,260,000
Free Float: 17,005,000
Market Cap: $8.54 million
Optionable: Optionable
Beta: 1.88

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Gregory Duncan (Age 58)
Chairman & CEO
Comp: $559.59k
Dr. William L. Pridgen M.D. (Age 63)
Founder & Director
Comp: $35k
Ms. Angela Walsh (Age 57)
CFO, SVP of Finance, Corporate Secretary & Treasurer
Comp: $281.28k
Dr. R. Michael Gendreau M.D. (Age 68)
Ph.D., Chief Medical Officer
Comp: $420.64k
Mr. Ralph D. Grosswald M.P.H. (Age 55)
Senior Vice President of Operations
Comp: $274.69k
Ms. Carol Duffy Ph.D.
Chief Scientific Advisor

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

VIRI Stock Analysis - Frequently Asked Questions

How have VIRI shares performed in 2024?: Virios Therapeutics' stock was trading at $0.5750 at the start of the year. Since then, VIRI shares have decreased by 24.3% and is now trading at $0.4355.
View the best growth stocks for 2024 here.
Are investors shorting Virios Therapeutics?: Virios Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 217,500 shares, an increase of 27.8% from the March 15th total of 170,200 shares. Based on an average daily trading volume, of 386,400 shares, the days-to-cover ratio is currently 0.6 days.
View Virios Therapeutics' Short Interest.
When is Virios Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VIRI earnings forecast.
How were Virios Therapeutics' earnings last quarter?: Virios Therapeutics, Inc. (NASDAQ:VIRI) announced its earnings results on Thursday, February, 29th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.03.

When did Virios Therapeutics IPO?: Virios Therapeutics (VIRI) raised $30 million in an initial public offering (IPO) on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.
How do I buy shares of Virios Therapeutics?: Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VIRI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Virios Therapeutics (VIRI) Stock Price, News & Analysis

Virios Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Virios Therapeutics Stock (NASDAQ:VIRI)

VIRI Stock Price History

VIRI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

VIRI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™